Close menu

August 18th, 2022 | 10:28 CEST

Defence Therapeutics CEO Sébastien Plouffe on the next steps in the battle against cancer

  • Expert
  • DefenceTherapeutics
  • Cancer
Photo credits:

A publicly traded biotechnology business called Defence Therapeutics is developing new vaccines and antibody-drug conjugates (ADC) products on its own proprietary platform. The ACCUM technology, which enables precise delivery of vaccine antigens or ADCs in their intact form to target cells, forms the basis of Defence Therapeutics' platform. As a result, catastrophic illnesses like cancer and infectious diseases can be combated with greater efficacy and potency. CEO Sébastien Plouffe gives us background on the company's latest development in the battle against cancer.

time to read: 1 minutes | Author: Mario Hose

Table of contents:

    Sébastien Plouffe, CEO and Director, Defence Therapeutics
    "[...] Accum™ helps us target active ingredients precisely to the origin of infections or diseases. [...]" Sébastien Plouffe, CEO and Director, Defence Therapeutics

    Full interview


    What is the advantage of the latest discovery from Defence Therapeutics and when do patients benefit from the progress in the battle against cancer?

    ‘The battle against cancer includes multiple but specific strategies directly targeting the tumor itself (e.g., CAR-T or immune-checkpoint blockers). However, tumor regression alone is not enough as the tumor being targeted can re-grow and leads to the formation of metastases all over the body. To limit this outcome, one needs to develop a therapeutic cancer vaccine capable not only of destroying tumor cells, but also eliciting the formation of long-term memory response capable of providing potent protection from subsequent tumor relapses.

    So far, dendritic cell-based vaccines were ineffective at achieving this goal, which is why Defence Therapeutics chose to adopt a different and unconventional approach by reprogramming mesenchymal stromal cells using its Accum technology to obtain powerful antigen presenting cells.

    With such an experimental therapeutic vaccine in hand, Defence is currently preparing an IND submission to initiate a Phase I trial in patients with solid tumors.’

    Sébastien Plouffe, CEO, Defence Therapeutics Inc.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author

    Related comments:

    Commented by Armin Schulz on September 6th, 2023 | 08:00 CEST

    BioNTech, Cardiol Therapeutics, Bayer - Tiger mosquitoes, and rising Corona numbers bring biotech back in focus

    • Biotechnology
    • Cancer
    • Covid19

    Corona infections are already rising, even though autumn has not even begun. Hospitals are already fearing a high burden during the winter. Gerald Gaß, the Chairman of the Board of the German Hospital Federation, advised high-risk patients, their close contacts and healthcare workers to keep their flu and COVID-19 vaccinations up to date. Due to constant stress triggered by crises and workload-related pressures, the number of heart patients have also increased in recent years. At the end of August, entire neighborhoods and streets in Paris were closed off to spray insecticides against tiger mosquitoes, which spread diseases like dengue and Zika viruses, among others. This is reason enough for us to examine three companies fighting these threats.


    Commented by Juliane Zielonka on July 21st, 2023 | 07:20 CEST

    BioNxt Solutions, Morphosys, Palantir - Innovative therapies for Parkinson's, cancer and soaring with AI

    • Biotechnology
    • Pharma
    • Cancer
    • AI
    • Technology

    There are exciting developments in the biotech industry. Thanks to innovative AI technologies, companies like BioNxt Solutions can analyze medical data faster and develop an innovative medical patch that provides Parkinson's patients with faster symptom relief. This patch carries the active ingredient rotigotine and has enormous market opportunities worldwide. Blockbuster-level market opportunities are emerging at Morphosys with regard to its compound pelabresib for the treatment of a rare form of blood cancer. The Phase III trial is expected to deliver results earlier than expected, and analysts see promising opportunities for the drug. According to a study by Bristol Myers Squibb, about 1.85 million new cases of blood cancer are expected worldwide in 2040. Deutsche Bank rated the stock "hold," driving the price up 4.9% this week. Also pushing upward is Palantir. The US company is getting into the drone business thanks to a partnership with Canada's Airmatrix.


    Commented by André Will-Laudien on June 30th, 2023 | 07:30 CEST

    Doublers are possible! Bayer, Defence Therapeutics, BioNTech, Valneva - It is hard to believe!

    • Biotechnology
    • Cancer
    • Pharma

    In 2022, a total of 19.5 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. However, thanks to growing research successes, there is hope that biotechnology will significantly increase the chances of survival for those affected. It is a matter of developing suitable active substances and launching modern therapies. mRNA technology has recently made a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. We are on the lookout for doubling potential.